Company news

Starpharma Holdings Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Upfront payment of USD $5.5 million received from Genentech

October 21, 2025

SPL: Research & Option Agreement with Radiopharm Theranostics

September 30, 2025

Starpharma Announces a Collaboration and License Agreement with Genentech

September 22, 2025

Presentation to Accompany License Agreement with Genentech

September 21, 2025

Starpharma Announces License Agreement with Genentech

September 21, 2025

$3.7M R&D Tax Incentive Received

August 27, 2025

FY25 Key Financial Results and Annual Report

August 26, 2025

2025 Appendix 4E Preliminary Financial Report

August 26, 2025

SPL receives positive FDA feedback on DEP SN38 for PROC

December 18, 2024

AGM Chair's address and CEO's presentation

November 26, 2024

SPL7013 Nasal Spray Australia Update

October 17, 2024

Starpharma Receives $5.5M R&D Tax Incentive Refund

September 11, 2024

Annual Report to shareholders

August 21, 2024

Positive final DEP irinotecan Phase 2 clinical trial results

May 27, 2024

Starpharma Business Update

May 22, 2024

Starpharma and Medicxi Partnership Petalion Therapeutics

April 7, 2024

S&P DJI Announces March 2024 Quarterly Rebalance

March 1, 2024

VivaGel BV US FDA Appeal Outcome

February 18, 2024

Viraleze shows antiviral efficacy in COVID-19 patients

January 28, 2024

VivaGel BV sales and distribution agreement MENA region

January 22, 2024

Positive DEP docetaxel Phase 2 results

December 18, 2023

AGM Chairman's address and CEO presentation

November 29, 2023

Starpharma announces new CEO, Ms Cheryl Maley

November 9, 2023

Starpharma receives $7.2 million R&D Tax Incentive refund

October 22, 2023

Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer

October 17, 2023

DEP irinotecan clinical data presented at AACR meeting

October 15, 2023

DEP irinotecan combination data presentation

September 26, 2023

VIRALEZ UK COVID-19 Clinical Study Completes Recruitment

September 25, 2023

Positive DEP irinotecan clinical results presentation

September 13, 2023

App 4E/Annual Report to shareholders

August 23, 2023

SPL to receive $6.5M from Mundipharma and VivaGel BV rights

August 13, 2023

Partnered Program Update

July 31, 2023

Trading Halt

July 28, 2023

Pause in Trading

July 28, 2023

Starpharma partners with UQ to advance DEP radio pipeline

July 25, 2023

DEP HER2-radiodiagnostic shows imaging benefits

July 20, 2023

Clinical Trial Update

June 27, 2023

Starpharma CEO to retire in 2024

June 8, 2023

VIRALEZE Nasal Spray Approved in Malaysia

June 5, 2023

HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model

April 26, 2023

Interim Report and Half-Year Financial Results

February 27, 2023

Quarterly Activities Report & Appendix 4C

January 29, 2023

Response to ASX Query Letters

January 12, 2023

Starpharma receives $7.1M R&D tax incentive refund

December 22, 2022

VIRALEZE Nasal Spray Registered in Indonesia

December 14, 2022

Positive AZD0466 clinical data presented by AstraZeneca

December 13, 2022

AGM Chairman address and CEO presentation

November 29, 2022

VIRALEZE distribution agreement for Hong Kong and Macau

October 20, 2022

New clinical data for DEP cabazitaxel in prostate cancer

September 11, 2022

S&P DJI Announces September 2022 Quarterly Rebalance

September 2, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 50 decks. Every deck is listed under its year.